Optimized fc variants and methods for their generation

(19)

(11)

EP 2 345 671 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	11.01.2023 Bulletin 2023/02

(45)	Mention of the grant of the patent:
	11.11.2015 Bulletin 2015/46

(21)	Application number: 10184682.2

(22)	Date of filing: 26.09.2003

(51)

International Patent Classification (IPC):

C07K 16/00^(2006.01)
C07K 16/28^(2006.01)

C07K 16/30^(2006.01)
C07K 16/24^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 2039/505; C07K 16/00; C07K 16/2893; C07K 16/2896; C07K 16/32; C07K 2317/72; C07K 2317/732; C07K 2317/734; C07K 2317/94; C07K 2317/34; A61P 25/00; A61P 29/00; A61P 31/00; A61P 35/00; A61P 37/00

(54)	Optimized fc variants and methods for their generation OPTIMIERTE FC VARIANTEN UND METHODEN ZU IHRER HERSTELLUNG Variantes FC optimisées et leurs procédés de génération

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30)

Priority:

27.09.2002 US 414433 P
23.01.2003 US 442301 P
02.05.2003 US 467606 P
12.06.2003 US 477839 P

(43)	Date of publication of application:
	20.07.2011 Bulletin 2011/29

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	08020666.7 / 2042517
	03773056.1 / 1553975

(73)	Proprietor: Xencor, Inc.
	Monrovia, CA 91016 (US)

(72)	Inventors:
	Lazar, Gregory Alan Glendale, CA 91202 (US) Chirino, Arthur J. Camarillo, CA 91106 (US) Dang, Wei Pasadena, CA 91101 (US) Desjarlais, John Rudolph Pasadena, CA 91104 (US) Doberstein, Stephen Kohn Pasadena, CA 91106 (US) Hayes, Robert J. Paoli, PA 19301 (US) Karki, Sher Busudur Pomona, CA 91767 (US) Vafa, Omid Phoenixville, PA 19460 (US)

(74)	Representative: HGF
	HGF Limited Saviour House 9 St. Saviourgate York YO1 8NQ York YO1 8NQ (GB)

(56)

References cited: :

WO-A2-00/42072

SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 9, 2 March 2001 (2001-03-02) , pages 6591-6604, XP2495886, ISSN: 0021-9258
JEFFERIS ROY ET AL: "Interaction sites on human IgG-Fc for FcgammaR: Current models", IMMUNOLOGY LETTERS, vol. 82, no. 1-2, 3 June 2002 (2002-06-03) , pages 57-65, XP002337953, ISSN: 0165-2478
CANFIELD S M ET AL: "THE BINDING AFFINITY OF HUMAN IGG FOR ITS HIGH AFFINITY FC RECEPTOR IS DETERMINED BY MULTIPLE AMINO ACIDS IN THE CH2 DOMAIN AND IS MODULATED BY THE HINGE REGION", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 173, no. 6, 1 June 1991 (1991-06-01), pages 1483-1491, XP001181027, ISSN: 0022-1007, DOI: DOI:10.1084/JEM.173.6.1483
SONDERMANN P ET AL: "The 3.2-ANG crystal structure of the human IgG1 Fc fragment-FcgammaRIII complex", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 406, no. 6793, 20 July 2000 (2000-07-20), pages 267-273, XP002343993, ISSN: 0028-0836, DOI: DOI:10.1038/35018508
IDUSOGIE ESOHE E ET AL: "Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 164, 1 January 2000 (2000-01-01), pages 4178-4184, XP002965858, ISSN: 0022-1767

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).